2026 Takes a Promising Turn in the Fight Against Cancer as Five Advances Offer New Hope
Globe Newswire (Wed, 7-Oct 9:59 AM ET)
NeOnc among Names with 2026 Breakthroughs that Offer New Hope in the Fight Against Cancer
Globe Newswire (Wed, 7-Oct 9:43 AM ET)
NeOnc's FDA Catalyst Run Could Give NTHI a Serious Jolt
Globe Newswire (Tue, 6-Oct 9:02 AM ET)
Biotech Brainiacs and Breakthroughs
Globe Newswire (Mon, 5-Oct 9:51 AM ET)
These High-Voltage Stocks Are Suddenly Impossible to Ignore
Globe Newswire (Fri, 2-Oct 11:44 AM ET)
3 Biotech Stocks Throwing Their Weight Around, and Another that Wants to Help You Lose Yours
Globe Newswire (Wed, 30-Sep 10:22 AM ET)
High-Stakes October has these Biotechs Entering Crucial Stretch
Globe Newswire (Tue, 29-Sep 12:12 PM ET)
NeOnc's Powerful Brain Cancer Pipeline Advances
Globe Newswire (Tue, 29-Sep 8:52 AM ET)
4 Explosive Stories Enter the Investor Spotlight
Globe Newswire (Mon, 28-Sep 11:51 AM ET)
Powerful NeOnc Brain Cancer Pipeline Advances
Globe Newswire (Mon, 28-Sep 9:51 AM ET)
NeOnc Technologies Holdings Inc. is a clinical-stage biopharmaceutical company focused on developing novel molecular technologies for the targeted delivery of therapeutics to treat central nervous system diseases. The company is developing drug delivery methods and drug candidates for intracranial malignancies such as gliomas, glioblastoma, and meningioma. Its lead product candidates include NEO100, an intranasal drug delivery therapy for brain cancer patients, and NEO212, an oral chemical conjugate designed to enhance treatment for glioblastoma.
Neonc Technologies Hldgs trades on the NASDAQ stock market under the symbol NTHI.
As of October 9, 2026, NTHI stock price climbed to $2.78 with 163,047 million shares trading.
NTHI has a beta of 2.37, meaning it tends to be more sensitive to market movements. NTHI has a correlation of 0.07 to the broad based SPY ETF.
NTHI has a market cap of $80.08 million. This is considered a Micro Cap stock.
The top ETF exchange traded funds that NTHI belongs to (by Net Assets): VTI, VXF, IWC, BUSM.
NTHI has underperformed the market in the last year with a price return of -77.0% while the SPY ETF gained +16.8%. NTHI has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -38.1% and -15.8%, respectively, while the SPY returned +4.7% and +1.5%, respectively.
NTHI support price is $2.33 and resistance is $2.73 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NTHI shares will trade within this expected range on the day.
